Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.69 |
| ▸ | PRCP | P42785 | 6/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061922 | 0.79 | PRCP (0.69) | KDM1APRCPGAAGID4RECQL | |
| SCHEMBL29924610 | 0.79 | PRCP (0.69) | KDM1APRCPGAAGID4RECQL | |
| SCHEMBL30721685 | 0.79 | PRCP (1.00) | KDM1APRCPGAAGID4RECQL | |
| SCHEMBL29478499 | 0.79 | PRCP (1.00) | KDM1APRCPGAAGID4RECQL | |
| SCHEMBL1668148 | 0.79 | PRCP (1.00) | KDM1APRCPGAAGID4RECQL | |
| SCHEMBL325083 | 0.79 | PRCP (1.00) | KDM1APRCPGAAGID4RECQL | |
| SCHEMBL327233 | 0.79 | PRCP (1.00) | KDM1APRCPGAAGID4RECQL | |
| SCHEMBL12046710 | 0.79 | PRCP (1.00) | KDM1APRCPGAAGID4RECQL | |
| SCHEMBL22728965 | 0.79 | PRCP (0.58) | KDM1APRCPGAAGID4RECQL | |
| SCHEMBL1694844 | 0.78 | PRCP (0.96) | KDM1APRCPGAAGID4RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4818726-B2 | — | — | 2011-11-16 | — | — | JP | claimed |
| CN-101553244-A | Treatment for intimal hyperplasia and related conditions | PROMICS PTY LTD (AU) | 2009-10-07 | — | — | CN | claimed |
| EP-1496929-A4 | USE OF C5A RECEPTOR ANTAGONIST IN THE TREATMENT OF FIBROSIS | PROMICS PTY LTD (AU) | 2009-08-26 | — | — | EP | claimed |
| EP-1558277-A4 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | PROMICS PTY LTD (AU) | 2009-07-29 | — | — | EP | claimed |
| EP-2049141-A1 | TREATMENT FOR INTIMAL HYPERPLASIA AND RELATED CONDITIONS | Promics Pty.,Ltd. (AU) | 2009-04-22 | — | — | EP | claimed |
| US-20080058252-A1 | Use of C5A receptor antagonist in the treatment of fibrosis | PROMICS PTY LIMITED (AU) | 2008-03-06 | — | — | US | claimed |
| WO-2008009062-A1 | TREATMENT FOR INTIMAL HYPERPLASIA AND RELATED CONDITIONS | PROMICS PTY LTD (AU) | 2008-01-24 | — | — | WO | claimed |
| US-20070054841-A1 | Method of treatment of systemic injury secondary to burns | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-03-08 | — | — | US | claimed |
| US-20070021329-A1 | Treatment of hypersensitivity conditions | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-01-25 | — | — | US | claimed |
| EP-1734981-A1 | TREATMENT OF NEUROLOGICAL CONDITIONS USING COMPLEMENT C5a RECEPTOR MODULATORS | Promics Pty Limited (AU) | 2006-12-27 | — | — | EP | claimed |
| CN-1604909-A | Cyclic peptides as G protein-coupled receptor antagonists | UNIV QUEENSLAND (AU) | 2005-04-06 | — | — | CN | claimed |
| EP-1496929-A1 | USE OF C5A RECEPTOR ANTAGONIST IN THE TREATMENT OF FIBROSIS | Promics Pty Limited (AU) | 2005-01-19 | — | — | EP | claimed |
| WO-2004103392-A1 | METHOD OF TREATMENT OF SYSTEMIC INJURY SECONDARY TO BURNS | THE UNIVERSITY OF QUEENSLAND (AU) | 2004-12-02 | — | — | WO | claimed |
| WO-2004100975-A1 | TREATMENT OF HAEMORRHAGIC SHOCK USING COMPLEMENT 5a RECEPTOR INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2004-11-25 | — | — | WO | claimed |
| EP-1444251-A1 | CYCLIC PEPTIDES AS G-PROTEIN-COUPLED RECEPTOR ANTAGONISTS | University of Queensland (AU) | 2004-08-11 | — | — | EP | claimed |
| WO-2004035080-A1 | TREATMENT OF HYPERSENSITIVITY CONDITIONS | THE UNIVERSITY OF QUEENSLAND (AU) | 2004-04-29 | — | — | WO | claimed |
| WO-2004035078-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | THE UNIVERSITY OF QUEENSLAND (AU) | 2004-04-29 | — | — | WO | claimed |
| WO-2004035079-A1 | TREATMENT OF OSTEOARTHRITIS | THE UNIVERSITY OF QUEENSLAND (AU) | 2004-04-29 | — | — | WO | claimed |
| WO-2003086448-A1 | USE OF C5A RECEPTOR ANTAGONIST IN THE TREATMENT OF FIBROSIS | PROMICS PTY LIMITED (AU) | 2003-10-23 | — | — | WO | claimed |
| WO-2003033528-A1 | CYCLIC PEPTIDES AS G-PROTEIN-COUPLED RECEPTOR ANTAGONISTS | UNIVERSITY OF QUEENSLAND (AU) | 2003-04-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021329-A1 | Treatment of hypersensitivity conditions | C3AR1, C5AR1, C5AR2 | KDM1A 4261/4885PRCP 731/4885GAA 2883/4885 |
| US-20080058252-A1 | Use of C5A receptor antagonist in the treatment of fibrosis | C3AR1, C5AR1, C5AR2 | KDM1A 3665/4885PRCP 1091/4885GAA 4767/4885 |
| US-20070054841-A1 | Method of treatment of systemic injury secondary to burns | C5AR2, C3AR1, C5AR1 | KDM1A 3746/4885PRCP 1666/4885GAA 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.